Recent policies to enhance Renin-angiotensin prescribing efficiency in Europe; implications for the future

Voncina, L. and Godman, B. B. and Vlahovic-Palcevski, V. and Bennie, M. and Bishop, I. (2011) Recent policies to enhance Renin-angiotensin prescribing efficiency in Europe; implications for the future. Pharmacoepidemiology and Drug Safety, 20 (Suppl.). S210-S210. 482. ISSN 1053-8569

Full text not available in this repository.Request a copy from the Strathclyde author

Abstract

Renin - angiotensin (RA) drugs (Angiotensin Converting Enzyme Inhibitors - ACEIs - and Angiotensin Receptor Blockers - ARBs) are accepted treatments for hypertension and Congestive Heart Failure. Coughing can occur with ACEIs leading to development of ARBs. Trials showed though discontinuation due to coughing in a minority of patients on ACEIs (2- - 3%). ARB prescribing restrictions in Austria as higher costs than ACEIs moderated utilisation. Other demand side measures in Spain (Catalonia) following generic ACEIs also moderated ARB utilisation.

ORCID iDs

Voncina, L., Godman, B. B., Vlahovic-Palcevski, V., Bennie, M. ORCID logoORCID: https://orcid.org/0000-0002-4046-629X and Bishop, I.;